Outcome of Adult Acute Myeloid Leukemia Expressing Lymphoid Markers
Abdelmoneem, S., Fathy, A., Al-Akkad, M., Abdel-motty, A., Embaby, A. (2025). Outcome of Adult Acute Myeloid Leukemia Expressing Lymphoid Markers. EKB Journal Management System, 31(1.1), 7-14. doi: 10.21608/zumj.2021.53818.2051
Shimaa Abdelmoneem; Ayman Fathy; Mohammad Al-Akkad; Alaa Abdel-motty; Ahmed Embaby. "Outcome of Adult Acute Myeloid Leukemia Expressing Lymphoid Markers". EKB Journal Management System, 31, 1.1, 2025, 7-14. doi: 10.21608/zumj.2021.53818.2051
Abdelmoneem, S., Fathy, A., Al-Akkad, M., Abdel-motty, A., Embaby, A. (2025). 'Outcome of Adult Acute Myeloid Leukemia Expressing Lymphoid Markers', EKB Journal Management System, 31(1.1), pp. 7-14. doi: 10.21608/zumj.2021.53818.2051
Abdelmoneem, S., Fathy, A., Al-Akkad, M., Abdel-motty, A., Embaby, A. Outcome of Adult Acute Myeloid Leukemia Expressing Lymphoid Markers. EKB Journal Management System, 2025; 31(1.1): 7-14. doi: 10.21608/zumj.2021.53818.2051

Outcome of Adult Acute Myeloid Leukemia Expressing Lymphoid Markers

Zagazig University Medical Journal
Article 2, Volume 31, Issue 1.1, January 2025, Page 7-14  XML PDF (1.03 MB)
Document Type: Original Article
DOI: 10.21608/zumj.2021.53818.2051
View on SCiNiTO View on SCiNiTO
Authors
Shimaa Abdelmoneem email 1; Ayman Fathy2; Mohammad Al-Akkad3; Alaa Abdel-mottyorcid 4; Ahmed Embabyorcid 3
1Internal medicine, Faculty of medicine, Zagazig university, Zagazig, Egypt
2Head of Hematology Unit, Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
3Clinical Hematology Unit, Internal Medicine,Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
4Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Abstract
Background:
Aberrant phenotype is a phenomenon in which lymphoid-associated and other myeloid lineage markers expressed in myeloblasts or myeloid-associated markers expressed in lymphoblasts. Occurrence of aberrant phenotype that has been reported in acute leukemias with varying frequency though its prognostic importance still remains controversial. So the aim of this prospective cohort study was evaluation the outcome of de novo AML patients expressing lymphoid markers(Ly+ AML) correlated with cytogenetic pattern and clinicobiological features.
Metods: our prospective cohort study designed to evaluate de novo adult patients having primary AML with the exclusion of acute promyelocytic leukemia admitted to the clinical Hematology Unit, Internal Medicine Department, in a tertiary referral hospital in Egypt, from July 2016 to the June 2019.
Results
Patients were classified according their lymphoid markers expression into two groups Ly+ AML and Ly- AML including; 23 (29.5%) and 55 (70.5%), respectively. After a median 8.133 months (range, 0.3-26 months) as a period of follow up, Ly+ AML patients group was associated with a significantly lower CR rate (p= 0.04). Moreover, Ly+ AML patients group was independently associated with complete response to therapy with OR [95%CI; 0.12-0.98], P=0.047 by using of the multivariate logistic regression model. Regarding survival, no statistical difference was showed in 26 months disease- free survival and overall survival as well.

Conclusion: lymphoid markers expression in AML patients was independently associated with Response to therapy. However, it was not reported as an independent predictor of survival.
Keywords
Acute myeloid leukemia; lymphoid markers expression; cytogenetic pattern; outcome
Statistics
Article View: 5,831
PDF Download: 56